R&D channel feed – Endpoints News

R&D channel feed

Gilead chief Daniel O’Day isn’t done making headlines — with more R&D deals and lots of new hires to come

6 years ago

Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom

6 years ago

Pedal to the metal, Amgen finally has a hot new drug star on its hands — and they have some news

6 years ago

Gates backs development work on a long-acting contraceptive pill

6 years ago

Eli Lilly axes an early-stage PD-L1/TIM-3 bispecific program in latest pipeline cleanup

6 years ago

The patent play: Biogen gets a PhIII boost for its bit-better take on the blockbuster MS franchise drug Tecfidera

6 years ago

After painting a poor safety profile, Pfizer and Eli Lilly are shooting for a new pain drug OK anyway

6 years ago

$20B-plus? Merck keeps racking up PhIII successes, scoring on triple negative breast cancer challenge as analysts drive up peak sales estimates

6 years ago

Novartis’ star blockbuster flunks closely watched PhIII — but they may file for key add-on OK anyway

6 years ago

Failed PhIIIs after a rejection by the FDA spur Sanofi to dump its $1.7B deal with Lexicon on diabetes drug — shares crash

6 years ago

AbbVie scraps an anti-tau study, and that may foretell more big trouble for a beleaguered Biogen

6 years ago

J&J touts their head-to-head win against Sanofi on MS, steering another S1P drug to the FDA

6 years ago

Allergan/Editas finally kick off CRISPR trial — marking first in vivo test of the gene-editing technology

6 years ago

Jupiter biotech scores $56M to defeat herpes, in a field littered with failure

6 years ago

The top 10 pipeline blowups, setbacks and snafus for H1 2019

6 years ago

Nektar takes a hit as the FDA swerves away from opioid reviews — leaving NKTR-181 in limbo

6 years ago

PARP inhibitors sometimes work beyond BRCA-mutations, researchers may finally know why

6 years ago

Vertex's Reshma Kewalramani takes CEO post as longtime vet Jeff Leiden moves to new role

6 years ago

Bristol-Myers does it again, disappointing investors with a surprise Opdivo PhIII failure as chemo combo flops

6 years ago

GSK culls more respiratory drugs out of PhII as focus shifts to cancer

6 years ago

As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ in a restructured global organization

6 years ago

Novartis, AstraZeneca vet Jonathan Symonds steers back to a top post in Big Pharma, this time at GSK

6 years ago

Stay tuned: Biogen’s numbers are great — it’s their worrisome future that leaves analysts skittish

6 years ago

Myovant's uterine fibroid drug looks competitive in PhIII — but can they vanquish mighty AbbVie?

6 years ago

First page Previous page 237 238 239240241 242 243 Next page Last page